753
Views
11
CrossRef citations to date
0
Altmetric
Original Articles

Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial

, , , &
Pages 1106-1119 | Accepted 21 Jun 2013, Published online: 19 Jul 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Yan-Shu Li, Wei Li, Qing-Sheng Zeng & Wei-Hua Fu. (2019) Effect of the imatinib treatment regimen on the postoperative prognosis of patients with high-risk gastrointestinal stromal tumors. OncoTargets and Therapy 12, pages 4713-4719.
Read now
Qi Liu, Fanmin Kong, Jianping Zhou, Ming Dong & Qi Dong. (2018) Management of hemorrhage in gastrointestinal stromal tumors: a review. Cancer Management and Research 10, pages 735-743.
Read now

Articles from other publishers (9)

Wan Qianyi, Xu Mei, Zhao Rui, Wang Yong, Wu Yutao, Shen Xiaoding & Wu Xiaoting. (2021) Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study. Journal of Cancer Research and Clinical Oncology 148:6, pages 1493-1500.
Crossref
Mingyang Feng, Yang Yang, Weiting Liao & Qiu Li. (2022) Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review. Frontiers in Public Health 9.
Crossref
Mohamad Farid, Johnny Ong, Claramae Chia, Grace Tan, Melissa Teo, Richard Quek, Jonathan Teh & David Matchar. (2020) Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis. Clinical Sarcoma Research 10:1.
Crossref
Thanaporn Bussabawalai, Kittiphong Thiboonboon & Yot Teerawattananon. (2019) Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand. Cost Effectiveness and Resource Allocation 17:1.
Crossref
Ulrikke J. V. Hernæs, Kjell A. Johansson, Trygve Ottersen & Ole F. Norheim. (2017) Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss. PharmacoEconomics 35:9, pages 965-974.
Crossref
Katherine A. Lyseng-Williamson. (2014) Imatinib: a guide to its use as adjuvant therapy for gastrointestinal stromal tumour (GIST) in the EU. Drugs & Therapy Perspectives 31:2, pages 45-51.
Crossref
Tadashi Kondo. 2015. General Methods in Biomarker Research and their Applications. General Methods in Biomarker Research and their Applications 251 266 .
Fabrice Smieliauskas, Chun-Ru Chien, Chan Shen, Daniel M. Geynisman & Ya-Chen Tina Shih. (2014) Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review. PharmacoEconomics 32:7, pages 651-680.
Crossref
Tadashi Kondo. 2014. General Methods in Biomarker Research and their Applications. General Methods in Biomarker Research and their Applications 1 13 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.